Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
New Ray Medicine International Holding's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was HK$-0.02.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.04.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 30.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
HKSE:06108'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -53.3 Med: -13.95 Max: 33.9
Current: 30.3
During the past 13 years, New Ray Medicine International Holding's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 33.90% per year. The lowest was -53.30% per year. And the median was -13.95% per year.
HKSE:06108's 3-Year EPS without NRI Growth Rate is ranked better than 74.1% of 502
companies
in the Healthcare Providers & Services industry
Industry Median: 10.7
vs HKSE:06108: 30.30
New Ray Medicine International Holding (HKSE:06108) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
New Ray Medicine International Holding EPS without NRI Related Terms
New Ray Medicine International Holding EPS without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Ray Medicine International Holding EPS without NRI Chart
New Ray Medicine International Holding Annual Data
New Ray Medicine International Holding EPS without NRI Competitor Comparison
For the Pharmaceutical Retailers subindustry, New Ray Medicine International Holding's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Ray Medicine International Holding PE Ratio without NRI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, New Ray Medicine International Holding's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where New Ray Medicine International Holding's PE Ratio without NRI falls into.
New Ray Medicine International Holding EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Ray Medicine International Holding (HKSE:06108) has a EPS without NRI of HK$-0.04 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on New Ray Medicine International Holding and its competitors. According to the industry distribution chart, New Ray Medicine International Holding ranks #130 out of 502 companies in the Healthcare Providers & Services industry, placing it in the top 25.9%.
Is New Ray Medicine International Holding's EPS without NRI too high?
New Ray Medicine International Holding's current EPS without NRI is HK$-0.04. Based on the distribution chart, New Ray Medicine International Holding ranks #130 out of 502 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, New Ray Medicine International Holding has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does New Ray Medicine International Holding's EPS without NRI compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, New Ray Medicine International Holding ranks #130 out of 502 companies for EPS without NRI. This puts New Ray Medicine International Holding in the upper half of its industry. The industry median EPS without NRI is 10.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 10.70, based on 502 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on New Ray Medicine International Holding and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 10.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. New Ray Medicine International Holding's current EPS without NRI is HK$-0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Ray Medicine International Holding stock overvalued right now?
Based on GuruFocus' analysis, New Ray Medicine International Holding (HKSE:06108) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.04, compared to a current price of HK$0.24 — trading 77.1% below its estimated fair value. The current EPS without NRI is HK$-0.04. New Ray Medicine International Holding's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For New Ray Medicine International Holding (HKSE:06108), the current EPS without NRI is HK$-0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is New Ray Medicine International Holding (HKSE:06108) Overvalued in 2026?
Based on GuruFocus' analysis, New Ray Medicine International Holding stock appears to be undervalued.
The current stock price of HK$0.24 is trading 77.1% below its estimated GF Value™ of HK$1.04.
GuruFocus considers New Ray Medicine International Holding to be Possible Value Trap.
Key valuation signals for HKSE:06108:
EPS without NRI: HK$-0.04
GF Value™: HK$1.04 vs. price of HK$0.24 (77.1% below fair value)
No single metric tells the full story. See the HKSE:06108 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
New Ray Medicine International Holding Ltd is engaged in the trading and distribution of pharmaceutical products in the People's Republic of China. The company's segments include the Distribution and trading of pharmaceutical products and the Provision of marketing and promotion services. Distribution and trading of pharmaceutical products segment consist of Injection drugs and generate maximum revenue for the company.
47GF Score
Get the complete analysis for HKSE:06108
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06108 has been successfully added to your 
